458 related articles for article (PubMed ID: 33961188)
21. Oral Delivery of Photopolymerizable Nanogels Loaded with Gemcitabine for Pancreatic Cancer Therapy: Formulation Design, and in vitro and in vivo Evaluations.
Yugatama A; Huang YL; Hsu MJ; Lin JP; Chao FC; Lam JKW; Hsieh CM
Int J Nanomedicine; 2024; 19():3753-3772. PubMed ID: 38686338
[TBL] [Abstract][Full Text] [Related]
22. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R
Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368
[TBL] [Abstract][Full Text] [Related]
23. Strategy for prevention of local recurrence of pancreatic cancer after pancreatectomy: antitumor effect of gemcitabine mixed with fibrin glue in an orthotopic nude mouse model.
Ogura Y; Mizumoto K; Tanaka M; Ohuchida K; Murakami M; Yamada D; Ishikawa N; Nagai E
Surgery; 2006 Jul; 140(1):66-71. PubMed ID: 16857444
[TBL] [Abstract][Full Text] [Related]
24. Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer.
Nakata B; Amano R; Nakao S; Tamura T; Shinto O; Hirakawa T; Okita Y; Yamada N; Hirakawa K
J Exp Clin Cancer Res; 2010 Feb; 29(1):15. PubMed ID: 20181235
[TBL] [Abstract][Full Text] [Related]
25. Preparation and characterization of gemcitabine liposome injections.
Zhou Q; Liu L; Zhang D; Fan X
Pharmazie; 2012 Oct; 67(10):844-7. PubMed ID: 23136718
[TBL] [Abstract][Full Text] [Related]
26. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
27. Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase.
Roman NO; Samulitis BK; Wisner L; Landowski TH; Dorr RT
Cancer Chemother Pharmacol; 2011 Jan; 67(1):183-92. PubMed ID: 20339847
[TBL] [Abstract][Full Text] [Related]
28. Combination of a novel microtubule inhibitor MBRI-001 and gemcitabine synergistically induces cell apoptosis by increasing DNA damage in pancreatic cancer cell lines.
Liu Y; Zang R; Li F; Shi C; Zhao J; Zhong L; Wang X; Yang J; Li W
Invest New Drugs; 2020 Oct; 38(5):1207-1217. PubMed ID: 31802375
[TBL] [Abstract][Full Text] [Related]
29. Gemcitabine-loaded Folic Acid Tagged Liposomes: Improved Pharmacokinetic and Biodistribution Profile.
Unnam S; Panduragaiah VM; Sidramappa MA; Muddana Eswara BR
Curr Drug Deliv; 2019; 16(2):111-122. PubMed ID: 30360740
[TBL] [Abstract][Full Text] [Related]
30. Mild hyperthermia enhances transport of liposomal gemcitabine and improves in vivo therapeutic response.
Kirui DK; Celia C; Molinaro R; Bansal SS; Cosco D; Fresta M; Shen H; Ferrari M
Adv Healthc Mater; 2015 May; 4(7):1092-103. PubMed ID: 25721343
[TBL] [Abstract][Full Text] [Related]
31. Gemcitabine loaded microbubbles for targeted chemo-sonodynamic therapy of pancreatic cancer.
Nesbitt H; Sheng Y; Kamila S; Logan K; Thomas K; Callan B; Taylor MA; Love M; O'Rourke D; Kelly P; Beguin E; Stride E; McHale AP; Callan JF
J Control Release; 2018 Jun; 279():8-16. PubMed ID: 29653222
[TBL] [Abstract][Full Text] [Related]
32. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
[TBL] [Abstract][Full Text] [Related]
33. Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts.
Nakahira S; Nakamori S; Tsujie M; Takeda S; Sugimoto K; Takahashi Y; Okami J; Marubashi S; Miyamoto A; Takeda Y; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Anticancer Res; 2008; 28(1A):179-86. PubMed ID: 18383843
[TBL] [Abstract][Full Text] [Related]
34. Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer.
Karaca M; Dutta R; Ozsoy Y; Mahato RI
Mol Pharm; 2016 Jun; 13(6):1822-32. PubMed ID: 26981724
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice.
Kim IY; Kang YS; Lee DS; Park HJ; Choi EK; Oh YK; Son HJ; Kim JS
J Control Release; 2009 Nov; 140(1):55-60. PubMed ID: 19616596
[TBL] [Abstract][Full Text] [Related]
36. Tumor-specific delivery of gemcitabine with activatable liposomes.
Tucci ST; Kheirolomoom A; Ingham ES; Mahakian LM; Tam SM; Foiret J; Hubbard NE; Borowsky AD; Baikoghli M; Cheng RH; Ferrara KW
J Control Release; 2019 Sep; 309():277-288. PubMed ID: 31301340
[TBL] [Abstract][Full Text] [Related]
37. Tumor targeting Salmonella typhimurium A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopic xenograft (PDOX) nude mouse models.
Kawaguchi K; Miyake K; Zhao M; Kiyuna T; Igarashi K; Miyake M; Higuchi T; Oshiro H; Bouvet M; Unno M; Hoffman RM
Cell Cycle; 2018; 17(16):2019-2026. PubMed ID: 29963961
[TBL] [Abstract][Full Text] [Related]
38. Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties.
Hong S; Fang Z; Jung HY; Yoon JH; Hong SS; Maeng HJ
Molecules; 2018 Oct; 23(10):. PubMed ID: 30314360
[TBL] [Abstract][Full Text] [Related]
39. Dual Enzymatic Reaction-Assisted Gemcitabine Delivery Systems for Programmed Pancreatic Cancer Therapy.
Han H; Valdepérez D; Jin Q; Yang B; Li Z; Wu Y; Pelaz B; Parak WJ; Ji J
ACS Nano; 2017 Feb; 11(2):1281-1291. PubMed ID: 28071891
[TBL] [Abstract][Full Text] [Related]
40. Co-delivery of autophagy inhibitor and gemcitabine using a pH-activatable core-shell nanobomb inhibits pancreatic cancer progression and metastasis.
Chen X; Tao Y; He M; Deng M; Guo R; Sheng Q; Wang X; Ren K; Li T; He X; Zang S; Zhang Z; Li M; He Q
Theranostics; 2021; 11(18):8692-8705. PubMed ID: 34522207
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]